Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2001

View Archived Issues

Recombinant hGH approved in E.U. for Turner's syndrome

BioMarin exercises option to product candidate for burns and wounds

Phogen and Atugen combine technologies in new alliance

Medarex and B. Twelve to develop human antibody therapeutics for cancer

Cellegy accelerates U.S. filing for Anogesic

Two new antiasthmatic compounds included in Inflazyme/Aventis alliance

Grant for paraoxonase research awarded to U. Michigan and Esperion

Binding and functional activity of the first truly selective alpha1A antagonist characterized

Scotia's Foscan receives negative opinion from EMEA

Roche highlights recent achievements in Japan

Dutch group identifies novel classes of adenosine receptor antagonists

Phytera achieves research milestone in antifungal drug collaboration with Lilly

Herbal remedy as a therapeutic option in premenstrual syndrome

Alista enters phase II evaluation for FSD

Second milestone achieved in Cubist/Novartis antiinfective alliance

NicOx's HCT-3012 moves into phase II clinical trials in Europe and the U.S.

Molecular mechanisms of antidiabetic and antiobesity effects of AJ-9677

Pexelizumab has a significant impact on outcome of CABG patients in phase II

CeNeS to market Xefo in the U.K.; product launch planned for 2001

Chemokine receptor antagonists designed at the former SmithKline Beecham

Antimalarial agents with a 2,3-dioxabicyclo[3.3.1]nonane structure

Sagami patents new series of immunosuppressants acting on protein phosphatase

Nymox and Biophage establish collaborative agreement for antimicrobial treatments

Inhibitors of PDE4 with antiasthmatic effects identified at Fuji Photo Film

Recent Japanese patent covers naturally occurring antiinflammatory agents

N-type calcium channel blockers and their use claimed in recent patent

New antibacterial peptide discovered at Meiji Milk Products

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...